ACE Report Cover
Tranexamic acid and fibrin spray equally effective in reducing blood loss following THA
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Language
Download Download Download
Download
Cite this Report Cite this Report Cite this Report
Cite
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favorites
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Language
Download Download Download
Download
Cite this Report Cite this Report Cite this Report
Cite
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favorites
ARTHROPLASTY
Tranexamic acid and fibrin spray equally effective in reducing blood loss following THA .
High Impact
This study has been identified as potentially high impact. OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself. Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone. This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(2):19 Acta Orthop. 2011 Dec;82(6):660-3. Epub 2011 Oct 17

66 patients undergoing primary unilateral cemented total hip replacement were randomized to receive treatment with either tranexamic acid, fibrin spray, or to the control group which received neither. The primary objective of this trial was compare total blood loss between these treatments. The results indicated that both tranexamic acid and fibrin spray were more effective in reducing the total blood loss than the control group. Neither of these active treatments were superior to one another.


Publication Funding Details +
Funding:
Not Reported
Conflicts:
None disclosed

Risk of Bias

6/10

Reporting Criteria

14/20

Fragility Index

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Yes = 1

Uncertain = 0.5

Not Relevant = 0

No = 0

The Reporting Criteria Assessment evaluates the transparency with which authors report the methodological and trial characteristics of the trial within the publication. The assessment is divided into five categories which are presented below.

1/4

Randomization

3/4

Outcome Measurements

4/4

Inclusion / Exclusion

3/4

Therapy Description

3/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

The Fragility Index is a tool that aids in the interpretation of significant findings, providing a measure of strength for a result. The Fragility Index represents the number of consecutive events that need to be added to a dichotomous outcome to make the finding no longer significant. A small number represents a weaker finding and a large number represents a stronger finding.

Why was this study needed now?

Various methods to achieve blood conservation following arthroplasty procedures of the lower limb have been used. Previous studies have shown that both tranexamic acid and fibrin spray are effective in reducing blood loss following total hip arthoplasties; however, direct comparisons of these two treatment have yet to be assessed.

What was the principal research question?

What is the effectiveness of fibrin spray compared to tranexamic acid on total blood loss, in patients undergoing total hip arthroplasty, measured post-operatively?

Study Characteristics +
Population:
66 patients undergoing primary unilateral cemented total hip arthroplasty.
Intervention:
Group 1: Patients given a 10mg/kg single dose of tranexamic acid at the beginning of surgery (n=22). Group 2: Patients received 10mL of fibrin spray given in divided doses peri-operatively (n=22).
Comparison:
Control group which did not receive either intervention treatment (n=22).
Outcomes:
The primary outcome was total blood loss (calculated using total blood volume and the change in hematocrit; pre-operative to post-operative).
Methods:
Randomized controlled trial; Single Centre; Multi-surgeon; Single Blind
Time:
Hematocrit, measured on second day after surgery, to determine the change in hematrocit levels, in order to calculate blood loss.
What were the important findings?
  • The calculated median total blood loss values are as follows: Control group= 1.20L (95% CI: 0.82-1.4; IQR: 0.50), tranexamic acid group=0.93L (95% CI: 0.69-1.1; IQR: 0.35), and the fibrin spray group=0.82L (95% CI 0.72-1.1; IQR: 0.33).
  • There was no significant difference in the total blood loss when comparing the two active treatment groups (p=1.0).
  • The tranexamic group had significantly lower blood loss compared to the control group (22% lower, p=0.02).
  • The fibrin spray group had a significantly lower blood loss than the control group (32% lower, p=0.02).
What should I remember most?

In patients undergoing total hip arthroplasty, both tranexamic acid and fibrin spray significantly reduced total blood loss in comparison to the control group. There were no differences in blood loss between tranexamic acid and fibrin spray groups.

How will this affect the care of my patients?

The use of either fibrin spray or tranexamic acid appear to be safe and efficacious treatments for blood conservation following total hip arthroplasty and should be considered as future treatment options. Further research is required to determine if these results extend to patients with uncemented total hip arthroplasties or arthroplasties in other joints.

DISCLAIMER

This content found on this page is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you require medical treatment, always seek the advice of your physician or go to your nearest emergency department. The opinions, beliefs, and viewpoints expressed by the individuals on the content found on this page do not reflect the opinions, beliefs, and viewpoints of OrthoEvidence.

0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Your account will be affiliated with
and includes free access to OrthoEvidence


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

How to cite this ACE Report

OrthoEvidence. Tranexamic acid and fibrin spray equally effective in reducing blood loss following THA. OE Journal. 2013;1(2):19. Available from: https://myorthoevidence.com/AceReport/Show/tranexamic-acid-and-fibrin-spray-equally-effective-in-reducing-blood-loss-following-tha

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report